Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379282738> ?p ?o ?g. }
Showing items 1 to 96 of
96
with 100 items per page.
- W4379282738 endingPage "e16019" @default.
- W4379282738 startingPage "e16019" @default.
- W4379282738 abstract "e16019 Background: Most patients with advanced GI cancers lack predictive biomarkers to determine response to systemic therapies. HTDS of PDTOs allows automated screening of large numbers of compounds to identify novel therapeutic options for refractory GI cancer patients in a rapid clinically meaningful way. Our objective was to determine the feasibility of HTDS on refractory GI PDTOs and to identify the concordance of ex-vivo sensitivity with clinical response to establish a new pipeline to reveal novel therapeutic options for GI cancer patients. Methods: Tumor tissues were obtained from advanced GI cancer patients anytime during their systemic therapies from needle biopsies or surgical specimens. PDTOs were established from these tumors at Englander Institute of Precision Medicine of Weill Cornell Medicine. Successful establishment of PDTOs occurs when they can be viably expanded beyond their initial plating in Matrigel for at least 5 passages and bio-banked. Whole exome sequencing and RNA sequencing confirmed genomic similarities between PDTOs and their originating tumors. PDTOs were screened for 156 drugs by using an integrative robotic HTDS system to examine drug sensitivity and validate patients’ clinical response. To determine clinical correlation, PDTOs ex-vivo response to FOLFOX, FOLFIRI, and docetaxel/paclitaxel (taxanes) were compared with their matching patients’ clinical response. Results: 30 PDTOs were established from 25 patients (11 colorectal, 14 gastroesophageal). Dose response curves for all 156 drugs were generated and subsequently AUC and IC50s were calculated. The concordance between PDTOs and patient’s response to FOLFOX, FOLFIRI and Taxane was determined for 31 PDTO-drug treatment iterations in which the patients also received same drug. 16/31 times the tissue was collected before the patient received the corresponding therapy and 15/31 times, afterwards. 2 patients were clinically non-evaluable. The overall concordance was 59% (17/29). Concordance was 64% (9/14) for specimens collected before patient receiving the therapy and 53% (8/15) for after. Concordance for FOLFOX was 71% (10/14), FOLFIRI 86% (6/7), Paclitaxel 14% (1/7) and Docetaxel 0% (0/1). Combined concordance for FOLFOX and FOLFIRI was 76%, and for specimens collected prior to clinical drug use, 80 % (8/10). Approx. 10% of drug screens revealed potential sensitive new treatment options such as Selinexor, Crizotinib, or Osimertinib for advanced GI cancer patients. Conclusions: We successfully demonstrated feasibility of an automated, end-to-end high-throughput screening of PTDOs in patients with refractory GI malignancies. PDTOs response highly correlated with clinical response, especially for FOLFOX and FOLFIRI. The HTDS identified several novel therapeutic options for advanced GI cancer patients." @default.
- W4379282738 created "2023-06-05" @default.
- W4379282738 creator A5000475484 @default.
- W4379282738 creator A5007372658 @default.
- W4379282738 creator A5014192350 @default.
- W4379282738 creator A5038396627 @default.
- W4379282738 creator A5041254900 @default.
- W4379282738 creator A5049924653 @default.
- W4379282738 creator A5077416215 @default.
- W4379282738 creator A5084749518 @default.
- W4379282738 creator A5086983128 @default.
- W4379282738 creator A5089202777 @default.
- W4379282738 date "2023-06-01" @default.
- W4379282738 modified "2023-09-23" @default.
- W4379282738 title "High-throughput drug screening (HTDS) of patient-derived tumor organoids (PTDO) from advanced gastrointestinal malignancies: Response and identification of novel therapeutic options." @default.
- W4379282738 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.e16019" @default.
- W4379282738 hasPublicationYear "2023" @default.
- W4379282738 type Work @default.
- W4379282738 citedByCount "0" @default.
- W4379282738 crossrefType "journal-article" @default.
- W4379282738 hasAuthorship W4379282738A5000475484 @default.
- W4379282738 hasAuthorship W4379282738A5007372658 @default.
- W4379282738 hasAuthorship W4379282738A5014192350 @default.
- W4379282738 hasAuthorship W4379282738A5038396627 @default.
- W4379282738 hasAuthorship W4379282738A5041254900 @default.
- W4379282738 hasAuthorship W4379282738A5049924653 @default.
- W4379282738 hasAuthorship W4379282738A5077416215 @default.
- W4379282738 hasAuthorship W4379282738A5084749518 @default.
- W4379282738 hasAuthorship W4379282738A5086983128 @default.
- W4379282738 hasAuthorship W4379282738A5089202777 @default.
- W4379282738 hasConcept C121608353 @default.
- W4379282738 hasConcept C126322002 @default.
- W4379282738 hasConcept C142724271 @default.
- W4379282738 hasConcept C143998085 @default.
- W4379282738 hasConcept C150903083 @default.
- W4379282738 hasConcept C160798450 @default.
- W4379282738 hasConcept C163763905 @default.
- W4379282738 hasConcept C207001950 @default.
- W4379282738 hasConcept C26291073 @default.
- W4379282738 hasConcept C2776705615 @default.
- W4379282738 hasConcept C2777292972 @default.
- W4379282738 hasConcept C2777511904 @default.
- W4379282738 hasConcept C2778260052 @default.
- W4379282738 hasConcept C2780035454 @default.
- W4379282738 hasConcept C2780259306 @default.
- W4379282738 hasConcept C2780962732 @default.
- W4379282738 hasConcept C2781187634 @default.
- W4379282738 hasConcept C2994119904 @default.
- W4379282738 hasConcept C526805850 @default.
- W4379282738 hasConcept C530470458 @default.
- W4379282738 hasConcept C71924100 @default.
- W4379282738 hasConcept C86803240 @default.
- W4379282738 hasConcept C98274493 @default.
- W4379282738 hasConceptScore W4379282738C121608353 @default.
- W4379282738 hasConceptScore W4379282738C126322002 @default.
- W4379282738 hasConceptScore W4379282738C142724271 @default.
- W4379282738 hasConceptScore W4379282738C143998085 @default.
- W4379282738 hasConceptScore W4379282738C150903083 @default.
- W4379282738 hasConceptScore W4379282738C160798450 @default.
- W4379282738 hasConceptScore W4379282738C163763905 @default.
- W4379282738 hasConceptScore W4379282738C207001950 @default.
- W4379282738 hasConceptScore W4379282738C26291073 @default.
- W4379282738 hasConceptScore W4379282738C2776705615 @default.
- W4379282738 hasConceptScore W4379282738C2777292972 @default.
- W4379282738 hasConceptScore W4379282738C2777511904 @default.
- W4379282738 hasConceptScore W4379282738C2778260052 @default.
- W4379282738 hasConceptScore W4379282738C2780035454 @default.
- W4379282738 hasConceptScore W4379282738C2780259306 @default.
- W4379282738 hasConceptScore W4379282738C2780962732 @default.
- W4379282738 hasConceptScore W4379282738C2781187634 @default.
- W4379282738 hasConceptScore W4379282738C2994119904 @default.
- W4379282738 hasConceptScore W4379282738C526805850 @default.
- W4379282738 hasConceptScore W4379282738C530470458 @default.
- W4379282738 hasConceptScore W4379282738C71924100 @default.
- W4379282738 hasConceptScore W4379282738C86803240 @default.
- W4379282738 hasConceptScore W4379282738C98274493 @default.
- W4379282738 hasIssue "16_suppl" @default.
- W4379282738 hasLocation W43792827381 @default.
- W4379282738 hasOpenAccess W4379282738 @default.
- W4379282738 hasPrimaryLocation W43792827381 @default.
- W4379282738 hasRelatedWork W1993599317 @default.
- W4379282738 hasRelatedWork W2242828348 @default.
- W4379282738 hasRelatedWork W2313360580 @default.
- W4379282738 hasRelatedWork W2333251263 @default.
- W4379282738 hasRelatedWork W2510242944 @default.
- W4379282738 hasRelatedWork W2589039513 @default.
- W4379282738 hasRelatedWork W2589571971 @default.
- W4379282738 hasRelatedWork W2591743724 @default.
- W4379282738 hasRelatedWork W2953872710 @default.
- W4379282738 hasRelatedWork W4379282738 @default.
- W4379282738 hasVolume "41" @default.
- W4379282738 isParatext "false" @default.
- W4379282738 isRetracted "false" @default.
- W4379282738 workType "article" @default.